ScholarIQanswers from OpenAlex & ORCID
Felipe A. Martínez
ResearcherPublications, citations & collaboration network
Felipe A. Martínez is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Felipe A. Martínez have?
ScholarIQindexed works
Felipe A. Martínez has 240 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Felipe A. Martínez have?
ScholarIQcitation count
Felipe A. Martínez has 33,533 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Felipe A. Martínez?
ScholarIQh-index
Felipe A. Martínez has an h-index of 61 in OpenAlex.
What is the i10-index of Felipe A. Martínez?
ScholarIQi10-index
Felipe A. Martínez has an i10-index of 147 in OpenAlex.
What is the ORCID of Felipe A. Martínez?
ScholarIQorcid
The ORCID for Felipe A. Martínez is on the source record.
What is the OpenAlex record for Felipe A. Martínez?
ScholarIQopenalex
The OpenAlex for Felipe A. Martínez is on the source record.
What are the most-cited papers on Felipe A. Martínez?
ScholarIQmost cited works
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski, Marc S. Sabatine, Inder S. Anand, Jan Bělohlávek, Michael Böhm, Chern‐En Chiang, Vijay Chopra, Rudolf A. de Boer, Akshay S. Desai, Mirta Díez, Jarosław Dróżdż, Andrej Dukát, Junbo Ge, Jonathan G. Howlett, Tzvetana Katova, Masafumi Kitakaze, Charlotta Ljungman, Béla Merkely, José Carlos Nicolau, Eileen O’Meara, Mark C. Petrie, Pham Nguyễn Vinh, Morten Schou, С. Н. Терещенко, Subodh Verma, Claes Held, David L. DeMets, Kieran F. Docherty, Pardeep S. Jhund, Olof Bengtsson, Mikaela Sjöstrand, Anna-Maria Langkilde
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Bertram Pitt, Willem J. Remme, Faı̈ez Zannad, James D. Neaton, Felipe A. Martínez, Barbara Roniker, Richard M. Bittman, Steve Hurley, Jay H. Kleiman, Marjorie Gatlin
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Scott D. Solomon, John J.V. McMurray, Brian Claggett, Rudolf A. de Boer, David L. DeMets, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez, Sanjiv J. Shah, Akshay S. Desai, Pardeep S. Jhund, Jan Bělohlávek, Chern‐En Chiang, C. Jan Willem Borleffs, Josep Comín‐Colet, Dan Dobreanu, Jarosław Dróżdż, James C. Fang, Marco A. Alcocer‐Gamba, Waleed Al Habeeb, Yaling Han, Jose Walter Cabrera Honorio, Stefan Janssens, Tzvetana Katova, Masafumi Kitakaze, Béla Merkely, Eileen O’Meara, José Francisco Kerr Saraiva, С. Н. Терещенко, Jorge Thierer, Muthiah Vaduganathan, Orly Vardeny, Subodh Verma, Vinh Pham, Ulrica Wilderäng, Natalia Zaozerska, Erasmus Bachus, Daniel Lindholm, Magnus Petersson, Anna Maria Langkilde
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Scott D. Solomon, John J.V. McMurray, Inder S. Anand, Junbo Ge, Carolyn S.P. Lam, Aldo P. Maggioni, Felipe A. Martínez, Milton Packer, Marc A. Pfeffer, Burkert Pieske, Margaret M. Redfield, Jean L. Rouleau, Dirk J. van Veldhuisen, Faı̈ez Zannad, Michael R. Zile, Akshay S. Desai, Brian Claggett, Pardeep S. Jhund, S. А. Boytsov, Josep Comín‐Colet, John G.F. Cleland, Hans‐Dirk Düngen, Eva Gonçalvesová, Tzvetana Katova, Jose F. Kerr Saraiva, Małgorzata Lelonek, Béla Merkely, Michele Senni, Sanjiv J. Shah, Jingmin Zhou, Adel R. Rizkala, Jianjian Gong, Victor Shi, Martin Lefkowitz
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Muthiah Vaduganathan, Kieran F. Docherty, Brian Claggett, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez, Sanjiv J. Shah, Akshay S. Desai, John J.V. McMurray, Scott D. Solomon